rs121907896
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP4
The NM_144585.4(SLC22A12):c.269G>A(p.Arg90His) variant causes a missense change. The variant allele was found at a frequency of 0.000103 in 1,612,014 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00010 ( 1 hom. )
Consequence
SLC22A12
NM_144585.4 missense
NM_144585.4 missense
Scores
2
11
6
Clinical Significance
Conservation
PhyloP100: 5.17
Genes affected
SLC22A12 (HGNC:17989): (solute carrier family 22 member 12) The protein encoded by this gene is a member of the organic anion transporter (OAT) family, and it acts as a urate transporter to regulate urate levels in blood. This protein is an integral membrane protein primarily found in epithelial cells of the proximal tubule of the kidney. An elevated level of serum urate, hyperuricemia, is associated with increased incidences of gout, and mutations in this gene cause renal hypouricemia type 1. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-64591825-G-A is Pathogenic according to our data. Variant chr11-64591825-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 3516.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP4
Computational evidence support a benign effect (MetaRNN=0.1300683). . Strength limited to SUPPORTING due to the PP5.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC22A12 | NM_144585.4 | c.269G>A | p.Arg90His | missense_variant | 1/10 | ENST00000377574.6 | NP_653186.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC22A12 | ENST00000377574.6 | c.269G>A | p.Arg90His | missense_variant | 1/10 | 1 | NM_144585.4 | ENSP00000366797.1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152178Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
13
AN:
152178
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000178 AC: 44AN: 246684Hom.: 0 AF XY: 0.000224 AC XY: 30AN XY: 134192
GnomAD3 exomes
AF:
AC:
44
AN:
246684
Hom.:
AF XY:
AC XY:
30
AN XY:
134192
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000105 AC: 153AN: 1459718Hom.: 1 Cov.: 35 AF XY: 0.000107 AC XY: 78AN XY: 726262
GnomAD4 exome
AF:
AC:
153
AN:
1459718
Hom.:
Cov.:
35
AF XY:
AC XY:
78
AN XY:
726262
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.0000537 AC XY: 4AN XY: 74468
GnomAD4 genome
AF:
AC:
13
AN:
152296
Hom.:
Cov.:
32
AF XY:
AC XY:
4
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
22
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Dalmatian hypouricemia Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 29, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | Across several studies, the SLC22A12 c.269G>A (p.Arg90His) missense variant has been reported in at least 18 individuals with renal hypouricemia including two homozygotes, 15 compound heterozygotes, and one heterozygote, who present with phenotypes ranging from no clinical symptoms to acute kidney injury after strenuous exercise (Ichida et al. 2004; Iwai et al. 2004; Ishikawa et al. 2005; Cheong et al. 2005; Komatsuda et al. 2006; Inazu et al. 2007; Ichida et al. 2008; Lee et al. 2008; Ochi et al. 2012). Ishikawa et al. (2005) noted that the p.Arg90His variant segregated with disease in multiple members of a large family. The variant was absent from 192 controls, but is reported at a frequency of 0.00237 in the East Asian population of the Exome Aggregation Consortium. Ichida et al. (2004) demonstrated that urate transport activity for the p.Arg90His variant in Xenopus oocytes was significantly decreased in comparison with that of wild type and was similar to that of oocytes that were not injected with URAT1 cRNA. Ichida et al. (2004) also demonstrated through immunocytochemical analysis that the variant exhibited similar staining patterns to wild type in the plasma membrane of Xenopus oocytes. Based on the collective evidence, the p.Arg90His variant is classified as pathogenic for renal hypouricemia. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.018%). Missense changes are a common disease-causing mechanism. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000003516). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 15741204, 16703794, 22045201). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Mar 21, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Dec 18, 2024 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 12, 2022 | This missense change has been observed in individual(s) with renal hypouricemia (PMID: 15741204, 16703794, 18492088, 30097038). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects SLC22A12 function (PMID: 33821957). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 3516). This variant is present in population databases (rs121907896, gnomAD 0.2%). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 90 of the SLC22A12 protein (p.Arg90His). - |
Familial renal hypouricemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 21, 2018 | The p.Arg90His variant in SLC22A12 has been identified in the homozygous or comp ound heterozygous state in at least 10 individuals with hypouricemia, most of wh om had Asian ancestry, (Iwai 2004, Ichida 2004, Komatsuda 2006, Inazu 2007, Lee 2008, Tasic 2011) and segregated with disease in 2 affected members from 1 famil y (Ishikawa 2005). All of these individuals had biochemical features consistent with hypouricemia, but only a subset were clinically affected. In vitro function al studies support an impact to protein function (Ichida 2004). This variant has been identified in 0.2% (37/17126) of East Asian chromosomes by gnomAD (http:// gnomad.broadinstitute.org). This frequency is consistent with the reported reduc ed penetrance for this disorder. In summary, this variant meets criteria to be c lassified as pathogenic for autosomal recessive hereditary renal hypouricemia, w hich has significantly reduced clinical penetrance, based on case observations a nd segregation studies. ACMG/AMP Criteria applied: PM3_VeryStrong, PP1_Moderate. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Pathogenic
DEOGEN2
Uncertain
.;D;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D;D
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Pathogenic
M;M;M;M
PrimateAI
Benign
T
PROVEAN
Uncertain
D;D;D;D
REVEL
Uncertain
Sift
Benign
T;D;T;D
Sift4G
Uncertain
D;D;D;D
Polyphen
D;D;D;.
Vest4
MPC
0.96
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at